Christopher Melani

Clinician and researcher specializing in lymphoma. Tweets are my own.

[Christopher Melani @MelanicjMD]

Great option for your R/R non-GCB and HGBCL-DH-BCL2 patients that can be used pre- or post-CAR-T. Already 1/3 accrued so refer your patients soon or consider opening at your site so you don’t miss out on this novel treatment option!!!

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more: https://t.co/hfbZzO89Q7 cc: @BloodCancerUtd, @lymphomahub

[Toby Eyre @tobyeyre82]

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial - The Lancet https://t.co/bOPpKGjJVw

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

I used to be a vocal skeptic of Hans and a key GEP fan, some say as an OG for GEP. I used to lament Hans IHC as the only tool available for my patients, when many trials used GEP instead.

But I have been surprised by learning how IHC has dramatically improved over the last decade or so with availability of standardized antibody clones, use of auto strainers, and interpretation consistency.

How was I convinced?

We did a systematic meta-analysis of >2200 patients from 19 studies. We used the PRISMA diagnostic test accuracy framework for comparing Hans to GEP.

https://t.co/qHJvtE7aFQ

Remarkably, this analysis now clearly shows that Hans is consistently non-inferior to GEP across current modern studies at a 10% NI margin for Accuracy, Precision, and Specificity.

This solid performance of Hans IHC is very much in line with current CAP benchmarks for diagnostic tests, and within the margins of NanoString GEP using FFPE vs original frozen GEP as the original elusive gold standard.

Long live Hans as the best currently available SOC for COO across the globe.

[Blood Cancer United @BloodCancerUtd]

When mantle cell lymphoma comes back, treatment choices have been limited.

The @FDA just approved a new treatment for MCL — on an expedited timeline, so it reaches patients sooner.
https://t.co/FXx93mRZQa

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more: https://t.co/hfbZzO89Q7 cc: @BloodCancerUtd, @lymphomahub

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy | Journal of Clinical Oncology https://t.co/Xs9LHIDjNF

[ECOG-ACRIN Cancer Research Group @eaonc]

Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: https://t.co/hfbZzO89Q7 #lymsm

[Christopher Melani @MelanicjMD]

Open to enrollment or soon to open in nearly 150 sites across the USA as of last month! Please consider referring patients or opening at your own site to access this promising treatment for your aggressive #lymphoma patients. @theNCI @lymphoma

[ECOG-ACRIN Cancer Research Group @eaonc]

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://t.co/hfbZzO89Q7 cc: @MelanicjMD, @theNCI, @UVACancerCenter

[Christopher Melani @MelanicjMD]

Currently enrolling patients with R/R CD10-negative DLBCL and HGBCL-DH-BCL2 across multiple EA sites in the USA including @theNCI. Please consider this encouraging study for your patients that may benefit!

[ECOG-ACRIN Cancer Research Group @eaonc]

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://t.co/hfbZzO89Q7 cc: @MelanicjMD, @theNCI, @UVACancerCenter

[Kate Cwynarski @CwynKate]

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology https://t.co/L6zjWfQdbO

[ECOG-ACRIN Cancer Research Group @eaonc]

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://t.co/hfbZzO89Q7 cc: @MelanicjMD, @theNCI, @UVACancerCenter

[Journal of Clinical Oncology @JCO_ASCO]

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L

Read the full article. https://t.co/GvDwbaivb4
#lymsm

[Mark Roschewski @RoschewskiMD]

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology https://t.co/jmQh4QsR3n

Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.

[Christopher Melani @MelanicjMD]

Excited to validate our single-center @theNCI findings in this multi-center phase II study in additional patients with #lymphoma. Please consider referring patients or opening at your site if interested.

[ECOG-ACRIN Cancer Research Group @eaonc]

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://t.co/hfbZzO89Q7 cc: @MelanicjMD, @theNCI, @UVACancerCenter

[ECOG-ACRIN Cancer Research Group @eaonc]

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: https://t.co/hfbZzO89Q7 cc: @MelanicjMD, @theNCI, @UVACancerCenter

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more info: https://t.co/hfbZzO89Q7 cc: @LLSusa, @lymphomahub

[Christopher Melani @MelanicjMD]

Such a thrill to watch @Hememachine receive the Henry Kaplan award at #ICML2025! Well deserved indeed and an honor to be able to review our #lymphoma cases weekly with her under the microscope @theNCI 👏🏻👏🏻👏🏻

[Michael Wang, MD @michaelwangmd]

Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. https://t.co/pYTN8qIsIk

[Christopher Melani @MelanicjMD]

Much deserved award to a leader in the field of mantle cell #lymphoma……BRAVO Martin 👏@lymphoma

[Christopher Melani @MelanicjMD]

Many thanks to @lymphoma for the opportunity to present data from our @theNCI study of ViPOR in mantle cell #lymphoma! Great meeting with great discussion from leaders in the field!